Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY2944876 vs Exenatide vs Placebo in T2D
NCT02119819Phase 2Completed
- Sponsor
- OPKO Health
- Start
- Apr 2014
- Primary completion
- Aug 2015
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 6
01
Overview
A Phase 2 trial of pegapamodutide in type 2 diabetes mellitus (T2DM), sponsored by OPKO Health. Started Apr 2014; status: completed.
02
Drugs
pegapamodutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02119819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02119819.